Iván R. González: Advances in the treatment of advanced ALK+ lung cancer

Iván R. González, Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla, shared a post on X:

“Advances in the treatment of advanced ALK+ lung cancer

(CROWNtrial):

Lorlatinib, a third-generation TKI, demonstrates a median progression-free survival of over 5 years in advanced ALK+ NSCLC, according to the CROWN trial.

With several second- and third-generation TKIs available, treatment selection should be based on the patient’s molecular profile.

Identification of high-risk profiles: The EML4-ALK V3 variant and TP53 mutations indicate a higher risk; monitoring with ctDNA can guide more personalized treatments.

New immunological strategies: Anti-ALK vaccines, such as those being evaluated in a new clinical trial (NCT05950139), show promise for advancing therapy.

Despite these advances, advanced ALK+ lung cancer remains a significant challenge that requires ongoing efforts to improve outcomes.”

New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 years

Author: Christine M. Lovly

Source: Iván R. González/X